As GLP-1 medications normalize smaller appetites and higher protein intake, national restaurant chains are quietly redesigning their menus — offering customers scaled-down portions at lower prices, whether they’re on the drugs or not. Once exclusively a treatment for diabetes, GLP-1 drugs such as Zepbound and Wegovy, which suppress appetite and slow digestion, have become a mainstream weight-loss tool . The drugs’ rise has coincided with a broader wellness and health-focused shift that seems to